Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-κB and endothelin-1
Pulmonary hypertension is rare in chronic respiratory diseases but has a strong impact on the prognosis and is partly underlined by factors other than hypoxaemia. The aim of the present study was to assess the potential role of endothelin-1 (ET-1) and nuclear factor (NF)-κB vasoconstrictive pathways...
Gespeichert in:
| Veröffentlicht in: | The European respiratory journal 2009-12, Vol.34 (6), p.1329-1337 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1337 |
|---|---|
| container_issue | 6 |
| container_start_page | 1329 |
| container_title | The European respiratory journal |
| container_volume | 34 |
| creator | HENNO, P MAUREY, C DANEL, C BONNETTE, P SOUILAMAS, R STERN, M DELCLAUX, C LEVY, M ISRAËL-BIET, D |
| description | Pulmonary hypertension is rare in chronic respiratory diseases but has a strong impact on the prognosis and is partly underlined by factors other than hypoxaemia. The aim of the present study was to assess the potential role of endothelin-1 (ET-1) and nuclear factor (NF)-κB vasoconstrictive pathways in pulmonary hypertension.
The effects of ET-1 receptors blockers (BQ 123 and 788) and of genistein were assessed on response to acetylcholine of pulmonary vascular rings from cystic fibrosis (CF) lung transplant recipients (n = 23). NF-κB and ET-1 receptor expression was immunodetected in pulmonary arteries and quantitated using Western blotting. ET-1 vascular content was quantitated using ELISA.
In total, 14 out of 23 subjects exhibited strongly impaired pulmonary vasodilation (p |
| doi_str_mv | 10.1183/09031936.00186908 |
| format | Article |
| fullrecord | <record><control><sourceid>pascalfrancis_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1183_09031936_00186908</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22162317</sourcerecordid><originalsourceid>FETCH-LOGICAL-c200t-2ab0418bebed085a529f51c9c346bd07068bbaabdef8fe8f450ac80ea9c9ad563</originalsourceid><addsrcrecordid>eNo9kE1OwzAQRi0EEqVwAHbesHQZx0lqs4OKAlIFLGCHFI3_wCh1qjhFytU4BGciUSmrWcz3RvM9Qs45zDiX4hIUCK5EOQPgslQgD8iEC6WYABCHZDLu2Rg4JicpfQ6pMhd8Qt6et_W6idj29AuT2dbYUtsnv42mC02kIVIXLUsdvjtq-tQFQ33QbZNCuqJtUzvaePq4ZD_fNxSjHdNN9-HqEBk_JUce6-TO_uaUvC5vXxb3bPV097C4XjGTAXQsQw05l9ppZ0EWWGTKF9woI_JSW5hDKbVG1NZ56Z30eQFoJDhURqEtSjElfHfXDH-l1vlq04b10KniUI16qr2eaq9nYC52zGaojbVvMZqQ_sEs42Um-Fz8AslaZr4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-κB and endothelin-1</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>HENNO, P ; MAUREY, C ; DANEL, C ; BONNETTE, P ; SOUILAMAS, R ; STERN, M ; DELCLAUX, C ; LEVY, M ; ISRAËL-BIET, D</creator><creatorcontrib>HENNO, P ; MAUREY, C ; DANEL, C ; BONNETTE, P ; SOUILAMAS, R ; STERN, M ; DELCLAUX, C ; LEVY, M ; ISRAËL-BIET, D</creatorcontrib><description>Pulmonary hypertension is rare in chronic respiratory diseases but has a strong impact on the prognosis and is partly underlined by factors other than hypoxaemia. The aim of the present study was to assess the potential role of endothelin-1 (ET-1) and nuclear factor (NF)-κB vasoconstrictive pathways in pulmonary hypertension.
The effects of ET-1 receptors blockers (BQ 123 and 788) and of genistein were assessed on response to acetylcholine of pulmonary vascular rings from cystic fibrosis (CF) lung transplant recipients (n = 23). NF-κB and ET-1 receptor expression was immunodetected in pulmonary arteries and quantitated using Western blotting. ET-1 vascular content was quantitated using ELISA.
In total, 14 out of 23 subjects exhibited strongly impaired pulmonary vasodilation (p<0.01 versus nine out of 23 subjects with a normal response) associated with an activation of ET-1 receptors A and NF-κB pathways. Genistein restored vasodilation in subjects with an abnormal response.
Pulmonary vascular dysfunction is frequent in end-stage CF, involving the NF-κB pathway and that of ET-1 through ET-1 receptor A (ETAR). These data leave a conceptual place for ETAR blockers and isoflavones in the management of the devastating vascular complication of chronic obstructive respiratory diseases such as CF.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/09031936.00186908</identifier><language>eng</language><publisher>Leeds: Maney</publisher><subject>Biological and medical sciences ; Chronic obstructive pulmonary disease, asthma ; Errors of metabolism ; Medical sciences ; Metabolic diseases ; Miscellaneous hereditary metabolic disorders ; Pneumology</subject><ispartof>The European respiratory journal, 2009-12, Vol.34 (6), p.1329-1337</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c200t-2ab0418bebed085a529f51c9c346bd07068bbaabdef8fe8f450ac80ea9c9ad563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22162317$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>HENNO, P</creatorcontrib><creatorcontrib>MAUREY, C</creatorcontrib><creatorcontrib>DANEL, C</creatorcontrib><creatorcontrib>BONNETTE, P</creatorcontrib><creatorcontrib>SOUILAMAS, R</creatorcontrib><creatorcontrib>STERN, M</creatorcontrib><creatorcontrib>DELCLAUX, C</creatorcontrib><creatorcontrib>LEVY, M</creatorcontrib><creatorcontrib>ISRAËL-BIET, D</creatorcontrib><title>Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-κB and endothelin-1</title><title>The European respiratory journal</title><description>Pulmonary hypertension is rare in chronic respiratory diseases but has a strong impact on the prognosis and is partly underlined by factors other than hypoxaemia. The aim of the present study was to assess the potential role of endothelin-1 (ET-1) and nuclear factor (NF)-κB vasoconstrictive pathways in pulmonary hypertension.
The effects of ET-1 receptors blockers (BQ 123 and 788) and of genistein were assessed on response to acetylcholine of pulmonary vascular rings from cystic fibrosis (CF) lung transplant recipients (n = 23). NF-κB and ET-1 receptor expression was immunodetected in pulmonary arteries and quantitated using Western blotting. ET-1 vascular content was quantitated using ELISA.
In total, 14 out of 23 subjects exhibited strongly impaired pulmonary vasodilation (p<0.01 versus nine out of 23 subjects with a normal response) associated with an activation of ET-1 receptors A and NF-κB pathways. Genistein restored vasodilation in subjects with an abnormal response.
Pulmonary vascular dysfunction is frequent in end-stage CF, involving the NF-κB pathway and that of ET-1 through ET-1 receptor A (ETAR). These data leave a conceptual place for ETAR blockers and isoflavones in the management of the devastating vascular complication of chronic obstructive respiratory diseases such as CF.</description><subject>Biological and medical sciences</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Errors of metabolism</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Miscellaneous hereditary metabolic disorders</subject><subject>Pneumology</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNo9kE1OwzAQRi0EEqVwAHbesHQZx0lqs4OKAlIFLGCHFI3_wCh1qjhFytU4BGciUSmrWcz3RvM9Qs45zDiX4hIUCK5EOQPgslQgD8iEC6WYABCHZDLu2Rg4JicpfQ6pMhd8Qt6et_W6idj29AuT2dbYUtsnv42mC02kIVIXLUsdvjtq-tQFQ33QbZNCuqJtUzvaePq4ZD_fNxSjHdNN9-HqEBk_JUce6-TO_uaUvC5vXxb3bPV097C4XjGTAXQsQw05l9ppZ0EWWGTKF9woI_JSW5hDKbVG1NZ56Z30eQFoJDhURqEtSjElfHfXDH-l1vlq04b10KniUI16qr2eaq9nYC52zGaojbVvMZqQ_sEs42Um-Fz8AslaZr4</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>HENNO, P</creator><creator>MAUREY, C</creator><creator>DANEL, C</creator><creator>BONNETTE, P</creator><creator>SOUILAMAS, R</creator><creator>STERN, M</creator><creator>DELCLAUX, C</creator><creator>LEVY, M</creator><creator>ISRAËL-BIET, D</creator><general>Maney</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20091201</creationdate><title>Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-κB and endothelin-1</title><author>HENNO, P ; MAUREY, C ; DANEL, C ; BONNETTE, P ; SOUILAMAS, R ; STERN, M ; DELCLAUX, C ; LEVY, M ; ISRAËL-BIET, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c200t-2ab0418bebed085a529f51c9c346bd07068bbaabdef8fe8f450ac80ea9c9ad563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Errors of metabolism</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Miscellaneous hereditary metabolic disorders</topic><topic>Pneumology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HENNO, P</creatorcontrib><creatorcontrib>MAUREY, C</creatorcontrib><creatorcontrib>DANEL, C</creatorcontrib><creatorcontrib>BONNETTE, P</creatorcontrib><creatorcontrib>SOUILAMAS, R</creatorcontrib><creatorcontrib>STERN, M</creatorcontrib><creatorcontrib>DELCLAUX, C</creatorcontrib><creatorcontrib>LEVY, M</creatorcontrib><creatorcontrib>ISRAËL-BIET, D</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HENNO, P</au><au>MAUREY, C</au><au>DANEL, C</au><au>BONNETTE, P</au><au>SOUILAMAS, R</au><au>STERN, M</au><au>DELCLAUX, C</au><au>LEVY, M</au><au>ISRAËL-BIET, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-κB and endothelin-1</atitle><jtitle>The European respiratory journal</jtitle><date>2009-12-01</date><risdate>2009</risdate><volume>34</volume><issue>6</issue><spage>1329</spage><epage>1337</epage><pages>1329-1337</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>Pulmonary hypertension is rare in chronic respiratory diseases but has a strong impact on the prognosis and is partly underlined by factors other than hypoxaemia. The aim of the present study was to assess the potential role of endothelin-1 (ET-1) and nuclear factor (NF)-κB vasoconstrictive pathways in pulmonary hypertension.
The effects of ET-1 receptors blockers (BQ 123 and 788) and of genistein were assessed on response to acetylcholine of pulmonary vascular rings from cystic fibrosis (CF) lung transplant recipients (n = 23). NF-κB and ET-1 receptor expression was immunodetected in pulmonary arteries and quantitated using Western blotting. ET-1 vascular content was quantitated using ELISA.
In total, 14 out of 23 subjects exhibited strongly impaired pulmonary vasodilation (p<0.01 versus nine out of 23 subjects with a normal response) associated with an activation of ET-1 receptors A and NF-κB pathways. Genistein restored vasodilation in subjects with an abnormal response.
Pulmonary vascular dysfunction is frequent in end-stage CF, involving the NF-κB pathway and that of ET-1 through ET-1 receptor A (ETAR). These data leave a conceptual place for ETAR blockers and isoflavones in the management of the devastating vascular complication of chronic obstructive respiratory diseases such as CF.</abstract><cop>Leeds</cop><pub>Maney</pub><doi>10.1183/09031936.00186908</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0903-1936 |
| ispartof | The European respiratory journal, 2009-12, Vol.34 (6), p.1329-1337 |
| issn | 0903-1936 1399-3003 |
| language | eng |
| recordid | cdi_crossref_primary_10_1183_09031936_00186908 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Biological and medical sciences Chronic obstructive pulmonary disease, asthma Errors of metabolism Medical sciences Metabolic diseases Miscellaneous hereditary metabolic disorders Pneumology |
| title | Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-κB and endothelin-1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A29%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pulmonary%20vascular%20dysfunction%20in%20end-stage%20cystic%20fibrosis:%20role%20of%20NF-%CE%BAB%20and%20endothelin-1&rft.jtitle=The%20European%20respiratory%20journal&rft.au=HENNO,%20P&rft.date=2009-12-01&rft.volume=34&rft.issue=6&rft.spage=1329&rft.epage=1337&rft.pages=1329-1337&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/09031936.00186908&rft_dat=%3Cpascalfrancis_cross%3E22162317%3C/pascalfrancis_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |